Jessica Serra | Head of Investor Relations and ESG |
Mark Foley | Chief Executive Officer |
Dustin Sjuts | President |
Toby Schilke | Chief Financial Officer |
David Amsellem | Piper Sandler |
Annabel Samimy | Stifel |
Seamus Fernandez | Guggenheim Securities |
Stacy Ku | Cowen |
Balaji Prasad | Barclays |
Lachlan Hanbury-Brown | William Blair |
Terence Flynn | Morgan Stanley |
Douglas Tsao | H.C. Wainwright |
Serge Belanger | Needham & Company |
Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Following managements’ prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, February 28, 2023.
I would now like to turn the conference over to Jessica Serra, Head of Investor Relations and ESG for Revance.